Haijun ma, PhD

Exelixis Inc.

Haijun Ma, PhD, is a passionate advocate for evidence-driven drug development and clinical trials, boasting over 18 years of industry experience in both big pharma and small to mid-sized biotechs. As a seasoned statistical leader, she excels in driving strategic, operational, and technical innovations across Phase I/II/III/IV clinical trials, post-marketing safety studies, and real-world data (RWD) initiatives. Haijun’s extensive scientific collaborations span industry, academia, and regulatory agencies, resulting in numerous peer-reviewed manuscripts and book chapters. Her expertise covers a wide range of areas, including clinical trial designs, RWD, pharmacoepidemiology, benefit-risk assessment, meta-analysis, survival analysis, and Bayesian statistics.

She holds a PhD in Biostatistics from the University of Minnesota Twin Cities and an MS in Statistics from Iowa State University. Currently, Haijun serves as the Executive Director of Biostatistics at Exelixis Inc., an oncology-focused biotech company dedicated to innovating cancer treatments. Prior to this role, she held positions of increasing responsibility at Amgen and Nektar Therapeutics. In a previous life, Haijun was also a translator of Mandarin/Spanish at the Consulate General of Chile in Shanghai, showcasing her diverse talents and interests.